Print Page  Close Window

News Release

MyoKardia Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Oct. 28, 2015-- MyoKardia, Inc. (“MyoKardia”) today announced the pricing of its initial public offering of 5,437,500 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by MyoKardia. In addition, MyoKardia has granted the underwriters a 30-day option to purchase up to an additional 815,625 shares of common stock from the company at the public offering price. The company's shares are expected to begin trading on The NASDAQ Global Select Market on October 29, 2015 under the ticker symbol “MYOK.” The offering is expected to close on November 3, 2015 subject to customary closing conditions.

Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as lead book-running managers. Wells Fargo Securities is acting as book-running manager. Wedbush PacGrow is acting as co-manager.

A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on October 28, 2015. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037, or by email at; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806 or by fax at (631) 254-7140.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Source: MyoKardia, Inc.

Pure Communications, Inc.
Media Contacts:
Katie Engleman, 910-509-3977
Investor Contacts:
Matt Clawson, 949-370-8500